STOCKHOLM, June 16, 2018 /PRNewswire/ --
B acute lymphoblastic leukemia (B-ALL) is a fatal blood cell tumor thatis usually treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HCT), and CD19-CAR-T cell therapy has been successful in treating refractory or relapsed (r/r) B-ALL patients. However, some patients would become refractory
(Logo: http://mma.prnewswire.com/media/622259/EHA_Logo.jpg )
Presenter: Dr Jing Pan
Affiliation: Beijing Boren Hospital, Beijing, China
Topic: EFFICACY AND SAFETY OF CD22-DIRECTED CAR-T CELL THERAPY IN 15 PEDIATRIC REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS.
Abstract S832 will be presented by Jing Pan on Saturday, June 16, 11:30-11:45 in Room A8.
About the EHA Annual Congress Every year in June, EHA organizes its Annual Congress in a major European city. After five years, the congress returns to Stockholm. The Congress is aimed at health professionals working in or interested in the field of hematology.
The scientific program topics range from stem cell physiology and development, to leukemia; lymphoma; diagnosis and treatment; red blood cells; white blood cells and platelet disorders; hemophilia and myeloma; thrombosis and bleeding disorders as well as transfusion and stem cell transplantation.
Embargo Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information check our Congress Media Guidelines here.
SOURCE European Hematology Association
Subscribe to our Free Newsletters!